Cel-Sci Corporation Price / Sales Ratio: 307.88
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CVM Price / Sales Ratio Rankings
| Overall | 0th percentile | 4358 of 4365 |
| Sector | 0th percentile | 454 of 457 in Healthcare |
| Industry | 2nd percentile | 121 of 124 in Biotechnology |
CVM Price / Sales Ratio Range, Past 5 Years
| Minimum | 16.95 | Sep 2002 |
| Maximum | 454.48 | Jun 2006 |
| Average |
About Price to Sales Ratio
The price to sales ratio (PS ratio) is calculated by dividing stock price by the revenue per share. It is most useful for comparing companies within a sector or industry because "normal" values for this ratio vary from industry to industry. In general, low price to sales ratios are more appealing because they suggest that a company is undervalued.
An example illustrating why PS ratios should not be compared across industries: On June 21, 2010, Starbucks had a PS ratio of 1.12 while Yahoo! had a PS ratio of 2.56. In other words, Yahoo! shareholders were paying $2.56 for $1 of sales while Starbucks shareholders would only pay $1.12 for $1 of sales. However, at that same moment, the two companies' price to earnings ratios were virtually identical (Starbucks: 28.09 and Yahoo!: 27.78). Hence, shareholders were paying nearly the same amount for $1.00 in earnings. The PS ratios, though, are less comparable since Yahoo!'s profit margins are much higher than that of Starbucks.
Learn More
You may also be interested in these CVM related companies
CVM News
CEL-SCI Corporation to Raise $5.76 Million in Registered Direct Offering
Jan 26, 9:15AM Business Wire
Jan 26, 9:15AM Business Wire
$INHX is done now $CVM and $IDIX will move look back in MAR11, I told you about INHX
about 25 days ago by JohnVan
about 25 days ago by JohnVan
$CVM Authorizes Expansion of Phase III Clinical Trial on Multikine to an Additional 4 European Countries
about 47 days ago by Benzinga
about 47 days ago by Benzinga
CEL-SCI (CVM) Expands Multikine Phase III to Spain, Czech Republic, Slovakia, Croatia
Dec 27, 8:46AM Street Insider
Dec 27, 8:46AM Street Insider
CEL- SCI Corporation Authorizes Expansion of Phase III Clinical Trial to an Additional 4 European Countries
Dec 27, 8:45AM Business Wire
Dec 27, 8:45AM Business Wire
URGENT: $CVM filed to delay releasing annual earnings results (SEC Filing Form NT 10K) http://stks.co/1ZNX
about 58 days ago by MarketBrief
about 58 days ago by MarketBrief
CEL-SCI updates phase 3 clinical activities for cancer therapy Multikine
Nov 02, 8:50AM FlyOnTheWall
Nov 02, 8:50AM FlyOnTheWall
Faster FDA Review Process Bodes Well for NPS Pharmaceuticals and Cel-Sci Corp
Nov 02, 8:16AM Marketwire
Nov 02, 8:16AM Marketwire
$CVM Great audio interview with CEO. Get good info - especially at the end - from the source, rather than the bashers here.
about 234 days ago by TriggerNews
about 234 days ago by TriggerNews
@adamfeuerstein Yeah I'm bearish as well... seems like a pretender. Their press releases are hilarious though. re: $CVM
about 256 days ago by Techinsidr
about 256 days ago by Techinsidr
@Techinsidr My uber-bearish position on $CVM is well known. It's a beast all right, but for all the wrong reasons. $EXCHTALK
about 256 days ago by adamfeuerstein
about 256 days ago by adamfeuerstein
@adamfeuerstein Hey Adam - any thoughts on $CVM? Got some friends who are convinced it's a beast... $EXCHTALK
about 256 days ago by Techinsidr
about 256 days ago by Techinsidr
@adamfeuerstein Hey Adam - any thoughts on $CVM ? Got a couple friends who are holding..
about 256 days ago by Techinsidr
about 256 days ago by Techinsidr
$CVM PR w/ 1q11 results and disclosing $12m legal settlement. Adding trial sites but no mention of any actual patients! http://stk.ly/jXFwVF
about 271 days ago by BioDueDiligence
about 271 days ago by BioDueDiligence
$cvm who else will be added to vanguard, blackrock barclays, maybe a sac :)
about 292 days ago by goldmanwho
about 292 days ago by goldmanwho
$cvm all the instituitional investors gone on yahoo finance web site, shorts scared:)
about 292 days ago by goldmanwho
about 292 days ago by goldmanwho
$CVM To Present Data Supporting Innovative Treatments for Cancer at World Vaccine Congress tomorrow April 14th
about 305 days ago by bricktop13
about 305 days ago by bricktop13
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CVM | 0.40 | -0.03 | -7.09% | 91.84M |
| UNP | 111.63 | -1.17 | -1.04% | 53.93B |
| BAC | 8.07 | -0.11 | -1.34% | 81.78B |
| CHS | 11.99 | 0.47 | 4.08% | 2.06B |
| FBP | 4.95 | 0.45 | 10.00% | 105.44M |
| CEL | 15.15 | -0.20 | -1.30% | 1.51B |
| FMC | 91.18 | -1.62 | -1.75% | 6.42B |
| CHT | 31.69 | -0.37 | -1.15% | 24.58B |
| MU | 7.91 | -0.26 | -3.12% | 7.81B |
| CNL | 39.24 | -0.26 | -0.66% | 2.40B |
